Biopharma firms are rethinking their contract development and manufacturing organization (CDMO) network against the backdrop of geopolitical tensions and the advancement of the US BIOSECURE Act, but the size of the shift away from China in the short and long term remains in question.
Key Takeaways
-
The BIOSECURE Act is causing firms to considering moving contract manufacturing to other countries, including India.
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?